Halozyme (HALO) Just Made A $1.3B Bet On Itself
On September 17, Halozyme (NASDAQ:HALO) priced $1.3 billion of convertible senior notes due 2033, an offering that grew from an originally planned $1.05 billion as demand came in.
Halozyme Therapeutics Inc. (HALO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | D E Shaw D. E. Shaw | 2,006,479 | $157,047,112 | +8% | 0.07% |
| 2. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 1,704,623 | $133,420,842 | -12% | 0.06% |
| 3. | 66,016,000 | $96,739,001 | +164% | 0.01% | |
| 4. | 45,000,000 | $65,812,500 | 0.25% | ||
| 5. | AQR Capital Management Cliff Asness | 785,556 | $61,485,452 | -23% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.24 | 17,543 | $249,780.74 | 277,553 | 2020-03-19 | Filing | |
| $14.25 | 17,543 | $249,982.49 | 260,010 | 2020-03-19 | Filing | |
| $14.19 | 17,543 | $248,933.42 | 242,467 | 2020-03-19 | Filing | |
| $17.24 | 10,000 | $172,384.00 | 10,000 | 2015-08-20 | Filing | |
| $17.24 | 10,000 | $172,384.00 | 10,000 | 2015-08-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $110.51 | 200 | $22,102.00 | 767,780 | 2026-10-08 | Filing | |
| $110.00 | 11,900 | $1,308,940.50 | 767,980 | 2026-10-08 | Filing | |
| $108.91 | 3,090 | $336,525.72 | 779,880 | 2026-10-08 | Filing | |
| $108.18 | 4,810 | $520,340.99 | 782,970 | 2026-10-08 | Filing | |
| $113.69 | 200 | $22,738.60 | 767,780 | 2026-10-07 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,281,615 | $251,890,296 | 1.63% | |
| 2. | 108,284 | $11,954,554 | 0.1% | |
| 3. | 28,511 | $3,147,640 | 0.66% | |
| 4. | 14,952 | $1,650,656 | 0.02% | |
| 5. | 11,625 | $1,283,400 | 0.33% |
News See All
Halozyme Therapeutics (HALO) Proposes $1.05B in Convertibles. Is More Time Worth the Cost?
Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on September 16 a proposed $1.05 billion offering of convertible senior notes due October 1, 2033.
Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics?
On July 20, Halozyme Therapeutics, Inc.
Q2 Earnings Blowouts: 37 Stocks That Beat Expectations
The ongoing earnings season has been a boon to listed companies' share prices in the second quarter of the year, helping offset macroeconomic uncertainties such as the US-Iran war, global trade, and questions...
8 Most Undervalued Growth Stocks to Buy for the Next 10 Years
Growth stocks aren’t supposed to be cheap. Investors willingly pay higher multiples for companies that are expected to grow earnings over the next few years.
Halozyme Therapeutics (HALO) Announces Global Collaboration and License Agreement With GSK
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best healthcare stocks to buy for the long term. Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2026 Earnings Call Transcript
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2026 Earnings Call Transcript May 11, 2026Halozyme Therapeutics, Inc. beats earnings expectations. Reported EPS is $1.6, expectations were $1.54.
H.C. Wainwright Bullish on Halozyme Therapeutics, Inc. (HALO) Commercial Revenue Outlook
We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. Halozyme Therapeutics, Inc. is one of the best cancer stocks to invest in. TheFly reported on April 29 that H.C.
10 Best Healthcare Stocks to Buy for the Long Term
In this article, we will look at the 10 Best Healthcare Stocks to Buy for the Long Term.
10 Best Cancer Stocks to Buy for the Long Term
In this article, we will be taking a look at the 10 Best Cancer Stocks to Buy for the Long Term.
Hedge Fund Resource Center